|Bid||3.6000 x 0|
|Ask||3.6100 x 0|
|Day's Range||3.4600 - 3.7100|
|52 Week Range||1.8100 - 6.0600|
|Beta (5Y Monthly)||1.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.75|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Recently announced preclinical data highlighting pelareorep's ability to synergize with multiple classes ...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), together with SOLTI, recently announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study showing patients receiving pelareorep plus checkpoint blockade therapy met the trial's primary endpoint. These data are featured in an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting 2021 during Week 1, which is taking place virtually from April 10-15, 2021.